These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21224087)

  • 21. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
    Murphy GP; Elgamal AA; Su SL; Bostwick DG; Holmes EH
    Cancer; 1998 Dec; 83(11):2259-69. PubMed ID: 9840525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA).
    Tykvart J; Navrátil V; Sedlák F; Corey E; Colombatti M; Fracasso G; Koukolík F; Bařinka C; Sácha P; Konvalinka J
    Prostate; 2014 Dec; 74(16):1674-90. PubMed ID: 25262926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine.
    Sokoloff RL; Norton KC; Gasior CL; Marker KM; Grauer LS
    Prostate; 2000 May; 43(2):150-7. PubMed ID: 10754531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Location of a protease-hypersensitive region in the multidrug resistance protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1.
    Hipfner DR; Almquist KC; Stride BD; Deeley RG; Cole SP
    Cancer Res; 1996 Jul; 56(14):3307-14. PubMed ID: 8764126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen.
    Kucinskaite-Kodze I; Pleckaityte M; Bremer CM; Seiz PL; Zilnyte M; Bulavaite A; Mickiene G; Zvirblis G; Sasnauskas K; Glebe D; Zvirbliene A
    Virus Res; 2016 Jan; 211():209-21. PubMed ID: 26541316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.
    Schroers R; Shen L; Rollins L; Xiao Z; Sonderstrup G; Slawin K; Huang XF; Chen SY
    Clin Cancer Res; 2003 Aug; 9(9):3260-71. PubMed ID: 12960111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology.
    Wang S; Diamond DL; Hass GM; Sokoloff R; Vessella RL
    Int J Cancer; 2001 Jun; 92(6):871-6. PubMed ID: 11351309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library.
    Ohyabu N; Hinou H; Matsushita T; Izumi R; Shimizu H; Kawamoto K; Numata Y; Togame H; Takemoto H; Kondo H; Nishimura S
    J Am Chem Soc; 2009 Dec; 131(47):17102-9. PubMed ID: 19899793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5.
    Lopes AD; Davis WL; Rosenstraus MJ; Uveges AJ; Gilman SC
    Cancer Res; 1990 Oct; 50(19):6423-9. PubMed ID: 1698122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker.
    Chang SS; Gaudin PB; Reuter VE; O'Keefe DS; Bacich DJ; Heston WD
    Mol Urol; 1999; 3(3):313-320. PubMed ID: 10851338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometric mapping of protein epitope structures of myocardial infarct markers myoglobin and troponin T.
    Macht M; Fiedler W; Kürzinger K; Przybylski M
    Biochemistry; 1996 Dec; 35(49):15633-9. PubMed ID: 8961925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein epitope mapping. I. Identification of a linear human-specific epitope in the fourth loop of the P-glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi-drug-resistant cells.
    Cianfriglia M; Willingham MC; Tombesi M; Scagliotti GV; Frasca G; Chersi A
    Int J Cancer; 1994 Jan; 56(1):153-60. PubMed ID: 7505264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.
    Garetto S; Sizzano F; Brusa D; Tizzani A; Malavasi F; Matera L
    Cytotherapy; 2009; 11(8):1090-100. PubMed ID: 19929472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of a prostate carcinoma mucin-like antigen (PMA).
    Beckett ML; Wright GL
    Int J Cancer; 1995 Sep; 62(6):703-10. PubMed ID: 7558418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The utility of monoclonal antibodies in the imaging of prostate cancer.
    Yao D; Trabulsi EJ; Kostakoglu L; Vallabhajosula S; Joyce MA; Nanus DM; Milowsky M; Liu H; Goldsmith SJ
    Semin Urol Oncol; 2002 Aug; 20(3):211-8. PubMed ID: 12215974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis.
    Kola A; Baensch M; Bautsch W; Hennecke M; Klos A; Casaretto M; Köhl J
    Immunotechnology; 1996 Jun; 2(2):115-26. PubMed ID: 9373320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the C-terminal end of the prostrate-specific antigen in a conformational epitope: characterization by proteolytic degradation of monoclonal antibody-bound antigen and mass spectrometry.
    Michel S; Forest E; Pétillot Y; Deléage G; Heuzé-Vourc'h N; Courty Y; Lascoux D; Jolivet M; Jolivet-Reynaud C
    J Mol Recognit; 2001; 14(6):406-13. PubMed ID: 11757074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients.
    Holmes EH; Greene TG; Tino WT; Boynton AL; Aldape HC; Misrock SL; Murphy GP
    Prostate Suppl; 1996; 7():25-9. PubMed ID: 8950359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.